Indivior applies for US FDA approval for schizophrenia drug, buys rival patent rights
Indivior
784.50p
16:34 04/10/24
Indivior has submitted a new drug application in the US for a once-monthly injectable schizophrenia treatment and agreed to buy out patent rights from a manufacturer of similar antipsychotic medication.
FTSE 250
20,900.08
17:14 04/10/24
FTSE 350
4,570.17
17:14 04/10/24
FTSE All-Share
4,527.24
16:54 04/10/24
Pharmaceuticals & Biotechnology
22,108.24
17:14 04/10/24
At the end of last week the FTSE 250 company filed an NDA with the US Food and Drug Administration for 'RBP-7000', an injectable version of antipsychotic medication risperidone that is administered via Atrigel, a slow-release drug delivery system.
Indivior, which makes most of its revenues from opioid addiction treatments, also said it had paid $12.5m up-front to Durect Corporation for "certain patent rights" to improve protection of RBP-7000, with a further $5m due upon NDA approval of RBP-7000 plus earn-out payments based on a low single-digit percentage of US sales of certain products covered by the patent rights.
The patent rights include a US patent that covers injectable sustained-release small molecule drug formulation, as well as pending applications in the same patent family.
Indivior's NDA submission for RBP-7000 included the results from a Phase 3 study testing the effectiveness and safety of the drug and a long-term safety study, which found the treatment demonstrated "statistically clinical improvement" compared to placebo based on changes in mean positive and negative syndrome scale total and clinical global impression-severity of illness scores at eight weeks.